How to access Ingrezza from India, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-24
An Indian patient with tardive dyskinesia (TD), or, per expanded labelling, chorea associated with Huntington's disease, may receive a prescription for Ingrezza (valbenazine) from their treating neurologist or psychiatrist. Ingrezza is FDA-approved for both indications, developed by Neurocrine Biosciences. It is not a controlled substance. In India, Ingrezza is not routinely registered for domestic outpatient dispensing, and access is typically coordinated through the named-patient import pathway under the Central Drugs Standard Control Organisation (CDSCO) framework.
This guide explains the pathway, documentation your physician prepares, typical timing and how quotes work, and where Reserve Meds fits in.
Ask about Ingrezza in India
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Ingrezza is an oral vesicular monoamine transporter 2 (VMAT2) inhibitor taken once daily, typically starting at 40 mg and titrated to 60 or 80 mg based on response and tolerability. The once-daily dosing profile is a convenience differentiator within the VMAT2-inhibitor class (deutetrabenazine is dosed twice daily).
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Eligibility for tardive dyskinesia requires documented exposure to dopamine receptor-blocking agents, typically antipsychotics, and persistent involuntary movements. Eligibility for Huntington's chorea requires genetic confirmation and a movement-disorder workup. Your neurologist or psychiatrist will establish baseline using the Abnormal Involuntary Movement Scale (AIMS) for TD or the Unified Huntington's Disease Rating Scale chorea score for Huntington's, screen for depression and suicidality (labelled warning for Huntington's patients), review QT interval (labelled QT-prolongation monitoring), and check hepatic function. Monitoring continues during titration and at subsequent visits.
Is Ingrezza legally importable into India?
Yes, through the CDSCO personal-import / named-patient framework administered under the Drugs and Cosmetics Rules. The mechanism permits import of an unregistered medicine for a specific named patient when (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent registered alternative is suitable for the patient, (c) a qualified Indian physician accepts clinical responsibility, and (d) chain of custody is documented. Both tardive dyskinesia and Huntington's chorea have limited disease-specific registered options in India, which is why named-patient imports are frequently used.
How the pathway works, step by step
- Consultation with your treating neurologist or psychiatrist. Indication documentation (TD exposure history or Huntington's genetic confirmation), movement-disorder scale baseline, and clinical rationale.
- Baseline assessment. AIMS or UHDRS-chorea baseline, depression/suicidality screen (for Huntington's patients), ECG for QT review, hepatic function.
- CDSCO named-patient application. The physician or hospital pharmacy files clinical rationale, patient reference, titration plan, and chain-of-custody commitment.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure Ingrezza from authorised distribution under DSCSA.
- Ambient shipment. Ingrezza ships under controlled ambient conditions with chain-of-custody documentation.
- Arrival and dispensing. The hospital pharmacy releases the bottle with titration and monitoring guidance.
What documentation your physician needs
- Clinical rationale letter confirming indication (TD or Huntington's chorea) and Ingrezza as the indicated therapy
- Verification of Indian medical registration (NMC / state council)
- AIMS score or UHDRS-chorea baseline
- Genetic confirmation report (for Huntington's)
- Depression/suicidality screen (for Huntington's patients, per labelling)
- Baseline ECG for QT interval and hepatic function tests
- Planned titration schedule and monitoring plan
Reserve Meds provides a physician documentation kit bundling templates CDSCO reviewers expect for movement-disorder named-patient imports.
Typical costs and indicative timing
Medicine price: quote on request. You get a written quote for your case before you commit. International logistics, CDSCO documentation handling, and coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake.
We give you a written timeline estimate for your case before you commit. Monthly refills are generally faster once the pathway is established.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
Reserve Meds's role
- Sourcing. Through our US-licensed pharmaceutical wholesale partner under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and CDSCO review.
- Logistics. Ambient-controlled shipment to your prescribing hospital pharmacy.
- Dedicated case lead. A named point of contact coordinating monthly refills.
What we do not do: we are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. All clinical decisions remain with your treating physician.
Frequently asked
Is this legal in India? Yes, when executed through the CDSCO named-patient / personal-import framework with appropriate documentation. See our trust and compliance page.
Is Ingrezza a controlled substance? No. Valbenazine is not a scheduled controlled substance.
How does Ingrezza compare with Austedo? Both are VMAT2 inhibitors for movement-disorder indications. Ingrezza is typically dosed once daily; Austedo is dosed twice daily (immediate-release) or once daily (Austedo XR). Your physician selects based on the specific indication, titration tolerability, and monitoring profile.
What is the suicidality warning? Ingrezza carries a labelled warning regarding depression and suicidal ideation/behaviour in Huntington's disease patients. Structured screening before and during therapy is required.
Why QT monitoring? VMAT2 inhibitors can prolong the QT interval in susceptible patients. A baseline ECG and avoidance in patients with significant QT prolongation or concurrent QT-prolonging medications is part of standard initiation.
Will private insurance cover this? Cash-pay is the default. Some Indian private insurers consider named-patient imports case by case; we supply documentation but do not process claims directly.
Next step
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We are not a pharmacy, not the prescriber, and not the manufacturer. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-04-24.
Frequently asked questions
How can I get Ingrezza in India if it is not approved or available there?
Reserve Meds coordinates US-sourced Ingrezza for patients in India through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for India and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Ingrezza in India through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Ingrezza. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in India, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Ingrezza in India through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Ingrezza to a patient in India?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Ingrezza to your treating physician or hospital pharmacy in India, with appropriate handling for the product.
How long does it take, and what does Ingrezza in India cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Ingrezza in India?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.